lenalidomide has been researched along with Amyotrophic Lateral Sclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beal, MF; Calingasan, NY; Hensley, K; Kiaei, M; Neymotin, A; Petri, S; Schafer, P; Stewart, C; Wille, E | 1 |
| Beal, MF; Calingasan, NY; Chen, J; Choi, DK; Gardian, G; Hensley, K; Kiaei, M; Kipiani, K; Muller, GW; Petri, S; Schafer, P; Stewart, C | 1 |
2 other study(ies) available for lenalidomide and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Body Weight; Cell Survival; Cytokines; Disease Models, Animal; Humans; Immunologic Factors; Lameness, Animal; Lenalidomide; Mice; Mice, Transgenic; Motor Neurons; Nerve Degeneration; Spinal Cord; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Analysis of Variance; Animals; Cell Count; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Fas Ligand Protein; Female; Fluorescent Antibody Technique; Glial Fibrillary Acidic Protein; Humans; Immunosuppressive Agents; Lenalidomide; Male; Membrane Glycoproteins; Mice; Mice, Transgenic; Middle Aged; Motor Activity; Neurons; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rotarod Performance Test; Superoxide Dismutase; Survival; Thalidomide; Time Factors; Tumor Necrosis Factor-alpha; Tumor Necrosis Factors | 2006 |